PDCD1LG2 and neoplasm: More recently, tumor cell expression of PD-L2, an important modulator of T-helper 2 cell responses15 has been independently correlated with the efficacy of PD-1 axis targeted inhibitors suggesting that the diversity in PD ligands expression might contribute to the heterogeneity of clinical responses to checkpoint inhibitors.16